Pharmacology, Biochemistry and Behavior 1995: Vol 51 Index

9 Pages·1995·2.6 MB·English

PHARMACOLOGY
BIOCHEMISTRY
AND
BEHAVIOR
VOLUME 51, 1995
SUBJECT AND AUTHOR INDEX
©
PERGAMON
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
Founded by MATTHEW J. WAYNER
US Editor-in-Chief European Editor-in-Chief
GEORGE F. Koos SANDRA E. FILE
Department of Neuropharmacology, CVN7 Psychopharmacology Research Unit
The Scripps Research Institute Guy’s Hospital Medical School
10666 N. Torrey Pines Road P.O. Box 3448
La Jolla, CA 92037, USA London SE1 9QH, UK
Fax: [phone] Fax: [phone]
E-mail: [email protected] E-mail: [email protected]
Editorial Advisory Board
LIISA AHTEE, Helsinki, Finland J. DAVID LEANDER, Indianapolis, IN
LEMBIT ALLIKMETS, Tartu, Estonia EMINY H. Y. LEE, Taipei, Taiwan
ROBERT L. BALSTER, Richmond, VA ALLEN S. LEVINE, Minneapolis, MN
GIOVANNI BIGGIO, Cagliari, Italy WILLIAM J. McBRIDE, Indianapolis, IN
MIKE BRILEY, Castres, France DONALD E. McMILLAN, Little Rock, AR
ALLAN C. COLLINS, Boulder, CO JACK H. MENDELSON, Belmont, MA
DONALD V. COSCINA, Toronto, Ontario, Canada FATHY S. MESSIHA, Grand Forks, ND
JACQUELINE N. CRAWLEY, Bethesda, MD ROBERT D. MYERS, Greenville, NC
ANNETTE DOMENEY, Geneva, Switzerland JUDITH A. PRATT, Glasgow, UK
ADRIAN J. DUNN, Shreveport, LA JAQUELINE SAGEN, Chicago, IL
BURR EICHELMAN, Philadelphia, PA ROSARIO SAMANIN, Milan, Italy
WILLIAM J. FREED, Washington, DC HERMAN H. SAMSON, Winston-Salem, NC
MANUEL FREIRE-GARABAL, Santiago De Compostela, Spain PAUL R. SANBERG, Tampa, FL
RICHARD A. GLENNON, Richmond, VA PHIL J. SKOLNICK, Bethesda, MD
F. G. GRAEFF, Sao Paulo, Brazil LINDA P. SPEAR, Binghamton, NY
M. R. C. GREENWOOD, Davis, CA CLARE STANFORD, London, UK
ROLAND R. GRIFFITHS, Baltimore, MD MARIE-HELENE THIEBOT, Paris, France
STEPHEN G. HOLTZMAN, Atlanta, GA DEREK VAN DER KOOY, Toronto, Ontario, Canada
AKIRA HORITA, Seattle, WA JEANNE M. WEHNER, Boulder, CO
CHRIS E. JOHANSON, Baltimore, MD BRUNO E. WILL, Strasbourg, France
HAROLD KALANT, Toronto, Ontario, Canada J. C. WINTER, Buffalo, NY
G. JEAN KANT, Washington, DC ALICE M. YOUNG, Detroit, MI
KATHLEEN M. KANTAK, Boston, MA IAN S. ZAGON, Hershey, PA
CONAN KORNETSKY, Boston, MA
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
Managing Editors:
In the US: In Europe:
Gery Schulteis Nick Andrews
E-mail: [email protected] E-mail: [email protected]
Production Editor:
Alayne A. Bakken
E-mail: [email protected]
Publishing, Subscription, and Advertising Offices:
Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA, E-mail Address:
[email protected]; and Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington,
Oxford OX5 1GB, England
Published Monthly
Annual Institutional Subscription Rates (1995): North, Central and South America, US$1580.00, Rest of World
£1060.00. Associated Personal Subscription Rates are available on request for those whose institutions are library
subscribers. Sterling prices exclude VAT. Non-VAT registered customers in the European Community will be
charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to
change without notice.
Pharmacology Biochemistry and Behavior is an official journal of the International Behavioral Neuroscience
Society. For information about the society, please contact: Marianne Van Wagner, IBNS Central Office, Division
of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West, San Antonio, TX 78249-
0662, USA. E-mail: [email protected]; Fax: (210) 691-4510. Members of the International
Behavioral Neuroscience Society may order personal subscriptions at a concessional rate; details of this rate are
available upon request.
Pharmacology Biochemistry and Behavior, Vol. 51, No. 4, pp. I-VIII, 1995
Copyright © 1995 Elsevier Science Ltd
Pergamon
Printed in the USA. All rights reserved
0091-3057/95 $9.50 + .00
SUBJECT INDEX
Abecarnil, 481 Apamin, 843 Cell mediated, 947
Absence epilepsy, 571 Apomorphine, 681 Central amygdala, 759
Acetic acid test, 675 Arachidonylethanolamide, 731 Central- and peripheral benzodiazepine
Acetylcholine, 739 Arthropoda, 223 receptors, 529
Actigraph, 509 Aspartic acid, 715 Cerebellum, 37, 139
Activity, 541 Atropine sulphate, 709 Cerebrospinal fluid, 139
Acute dependence, 407 Atypical antipsychotic, 561 c-fos, 331
Adaptability, 849 Aversion, 317, 457 CGS 8216, 499
Adenosine A, receptors, 133 Avoidance, 601 CGS 9896, 499
Adenosine A, receptors, 133 CGS 21680, 133
Adjuvant, 877 Barbiturates, 391 Challenge, 789
AF64A, 667 Barrel rotation, 37 ChAT, 935
AF102B, 623 BDB, 473, 477 Chemoreceptors, 125
AF150(S), 667 Behavior, 29, 263, 331, 353, 509 Chickens, 477, 795
Aggression, 789 Behavioral depression, 339 Chlordiazepoxide, 391, 481
Aggressive behavior, 767 Behaviour, 611 Chlorisondamine, 693
Aging, 541 Behavioural sensitization, 89 Cholecystokinin octapeptide, 9
Aging, memory decline, 557 Benzodiazepine(s), 363, 391, 499, 721, 815 Cholinergic, 369
AIDS, 947 Benzodiazepine antagonist, 557 Cholinergic deficit, 917
Alcohol drinking, 593 Benzodiazepine inverse agonist, 557 Cholinergic system, 279
Allopregnanolone, 463 Bestatin, 675 Cholinesterase, 443
a, Adrenoceptors, 789 6-Adrenergic receptor, 553 Cholinesterase inhibitor, 415
a-Methyl-p-tyrosine, 159 B-Adrenergic receptor subtypes, 339 Chronic administration, 435
Alternative model, 675 B-Adrenoceptors, 439 Chronic treatment, 77, 175, 635
Alzheimer’s disease, 509, 557, 667, B-Carboline, 795 Cinanserin, 313
Amantadine, 709 B-CIT, 953 Circadian, 947
Amineptine, 165 B-Endorphin, 577 Circadian rhythm, 541
Amitriptyline, 65, 623 Bicuculline, 363 Clonidine, 69, 263
Amobarbital, 391 Body core temperature, 217 Clozapine, 561
Amodiaquin, 843 Body temperature, 245 CNQX, 855
Amphetamine, 301, 397, 421, 725 Body weight gain, 725 CNS stimulants, 69
Amphetamine derivatives, 473 Brain, 57, 331, 593, 731 Cocaethylene, 285, 549
Amphibians, 675 Brain-gut axis, 139 Cocaine, 285, 313, 379, 521, 549, 661, 687,
Amygdala, 331 Brain selenium, 747 705, 759, 781, 827, 901, 953
Analgesia, 323, 535, 693, 699, 715 Brain stem, 581 Cocaine abuse, 661
Anandamide, 3, 731 Bretazenil, 481 Cocaine analogues, 953
Angiotensin antagonist, 593 Buspirone, 821 Cocaine sensitization, 799
Angiotensin II, 83, 593 Butyrylcholinesterase, 647 Cognitive deficits, 667
Angiotensin III, 593 Cold exposure, 217, 775
Animal model(s), 553, 947 C57BL/6J ‘mice, 827 Colonic temperature, 83
Animal hypnosis, 577 Color and position discrimination, 301
C57BL/6NNia mice, 557
Anorectics, 89 Caffeine, 941 Conditioned avoidance responses, 279
Anti-Parkinsonian drugs, 249 Conditioned defecation, 89
Caffeine deprivation, 941
Antagonist, 815 Conditioned fear, 407
Calcium ions, 133
Anticholinergic, 271 Conditioned fear stress, 515
Candida albicans, 877
Anticholinergic drug, 249 Conditioned locomotion, 89
Cannabinoid, 731
Antidepressant(s), 165, 331, 849 Conditioned place prefences, 89, 549
Cannabinoid receptors, 731
Antidepressant drugs, 565 Conditioning, 331
Cannabinoid receptor agonists, 3
Antinociception, 655, 855 Conflict behavior, 391, 635
Carassius, 885
Antioxidant enzymes, 627 Control of respiration, 133
Carbamates, 443
Antipredator defense, 235 Carbamazepine, 391 Convulsion, 309, 363
Antipsychotic drugs, 565 Convulsive threshold, 363
Cardiac, 509
Anxiety, 199, 211, 235 Carotid bodies, 133 Copulation, 439
Anxiogenic drug, 795 Cortical catecholamines, 861
Catalepsy, 175
Anxiolytics, 391, 635, 849 Corticosterone, 65, 789
Catecholamines, 789
APS, 855 Cortisone, 877
Cathinone, 473
CPP, 345
IV SUBJECT INDEX
Crab, 223 Escape, 601 Heart mitochondria, 627
CRF, 885 Escape-deficit, 339 Heroin, 491, 655
Cross-tolerance, 891 Estradiol, 279 Hippocampal plasticity, 869
Cyclosporine, 877 Estrogen, 807 Histamine H,-, H,-, and H,-receptors, 923
Estrous cycle, 279 Histamine receptor, 65
D, agonsit, 617 Ethanol, 189, 223, 285, 525, 549, 835, 891 Holeboard maze, 917
D, dopamine receptor, 767 Ethologic analysis, 331 Horizontal movement, 359
D, receptors, 681 Etorphine, 535 HS mice, 521
D,-discriminative stimuli, 77 Excitatory amino acid antagonists, 855 Human, 323, 509, 815, 941
D, partial agonists, 661 Excitatory amino acids, 205 Human studies, 189
D, receptors, 565, 681 Excitotoxic lesions, 739 Humoral, 947
DA and metabolite levels, 29 Exercise, 627, 725 Huperzine A, 415
DALDA, 149 Exploratory activity, 205 Hyperactivity, 13, 159
d-amphetamine, 69 Eye control, 37 Hyperphagia, 923
Darodipine, 183 Hypnotics, 571
Delayed matching-to-sample, 271, 509 F-344 rats, 775 Hyponeophagia, 199
Delayed nonmatching-to-sample task, 929 Fasting, 885 Hypothermia, 525, 891
6-Opioid agonist, 359 Fear, 235, 297, 331, 795 Hypoxia, 245
Delta opioid receptor, 655 Feeding, 641
A’-Tetrahydrocannabinol, 731 Feeding test, 499
Ibogaine, 103
Dementia of Alzheimer type, 917 Fenfluramine, 313, 641 ICS 205-930, 69, 835
Dependence, 469 Fentanyl, 535
Idazoxan, 69
Depression, 339, 553, 849 FG lesion, 935
Immediate early gene, 331
Descending pathway, 655 5-HT and metabolites levels, 29
Immunity, 947
Designer drugs, 473, 477 5-HT,, agonists, 235
Immunization, 877
Desipramine, 331 5-HT, antagonist, 353
In vivo microdialysis, 515
Development, 153 5-HT>;, antagonist, 235
Infection, 877, 947
Developmental course, 199 5-HT,, receptor(s), 211,317, 439
Inferior colliculus, 317
Diazepam, 65, 189, 391, 923 5-HT, receptors, 317
Ingestion, 505
Diethylpropion, 89 5-HT; receptor, 835
Ingestive behavior, 9
Digiscan, 13 5-HTP, 21
Initial subsensitivity, 391
Dihydrexidine, 521, 617, 767 5-Hydroxytryptamine, 9
Intracellular calcium, 57
Dihydroxyphenylacetic acid, 397 5-Hydroxytryptophan, 9
Intracerebroventricular, 593
Dimethylaminorex isomers, 375 Fixed-ratio discrimination learning, 861,
Intracranial self-administration, 49
Discriminative stimulus, 705 869
Intrathecal, 855
Divided attention, 189 Fixed interval, 481
Intravenous self-administration, 827
Dog, 421 Flight, 235 IO intake, 9
DOI, 21 Flumazenil, 557, 815 Ipsapirone, 217
Dopamine, 3, 69, 97, 159, 397, 521, 681, Flurazepam, 909
Isolation distress, 463
687, 835, 917 Food anticipation, 541
Isoproterenol, 83
Dopamine D, receptors, 759 Food deprivation, 499
Isradipine, 183
Dopamine D, receptors, 843 Food intake, 449, 725
Dopamine D, receptors, 843 Food palatability, 499
Dopamine receptor(s), 291, 545 Food reinforcement, 301 Kainic acid, 205
x-Opioid agonists, 611
Dopamine receptor antagonists, 799 Foot-shock, 515
Dopamine receptor occupancy, 175 Footshock, 407 Ketamine, 291
Ketanserin, 69
Dopamine transporter, 953 Forced swimming test, 849
Dopaminergic neuronal plasticity, 861 Formalin pain, 577 Kynureninase, 753
Kynurenine aminotransferase, 753
Dose discrimination, 49 Fos protein, 175
Kynurenines, 753
DPDPE, 57, 655 4-Aminopyridine, 843
Drinking, 83 4-Methylaminorex analogues, 375
Drug abuse, 375 Freezing behavior, 515 Lateral hypothalamus, 49
Drug dependence, 435 Fura2/AM, 57 Lateral ventricle, 593
Drug discrimination, 69, 379, 491, 561, LCGU, 935
661, 759, 953 GABA, 463, 795 L-Deprenyl, 421
Drug discrimination study, 375 GABA receptors, 529 Learned helplessness, 553
Dynorphin, 387 GABA,, 655 Learning, 13, 301, 509, 541
GABA, receptor, 721, 909 Learning and memory, 223
ECS, 565 - GABAs, 655 Learning deficits, 917
Ecstasy, 301 Gender differences, 601 Lethality, 249, 521, 781
EEG power spectra, 611 Gepirone, 235 Leukemia, 947
EEG spectral analysis, 353 Glucose, 885 Leukocytes, 339
8-OH-DPAT, 235 Glutathione, 627 Levamisole, 877
Electroconvulsive shock, 565 Glutathione peroxidase, 747 Light, 947
Emergence test, 297 Goldfish, 885 Limbic, 331
Emotionality ratings, 199 Linear locomotion, 149
Endogenous antioxidant system, 581 HJMK-801, 435 Linopirdine, 111
Enkephalin, 675 Habituation, 223 Locomotor activity, 149, 291, 359, 457,
Environmental enrichment, 397 Hallucinogen, 301 693, 827, 891, 901
Epibatidine, 693 Haloperidol, 175, 291, 601, 709, 843 Long-sleep, 525
Epilepsy model, 37 Head twitches, 183 Lorazepam, 189, 721
Epinephrine, 217, 255 Head shakes, 21 LS mice, 891
SUBJECT INDEX
Macaque monkey, 617 Nitrous oxide, 323, 815 Proestrus, 807
Male/female rats, 807 NMDA, 13, 901 Progesterone, 807
Male rat(s), 9, 439, 545 NMDA receptor, 133, 909 Properties, 705
Marmosets, 443 NMDA receptor complex, 635 Propoxyphene, 535
Maternal separation, 463 N-Methyl-D-aspartate, 249 Propranolol, 69, 439, 255, 297
MCI-225, 935 N-Methyl-D-aspartate antagonists, 249 Proprioception, 37
MDMA, 301 N-Methyl-D-aspartate receptor(s), 291, 309 Psychomotor stimulants, 89
Mean platelet volume, 217 N-Methyl-D-aspartic acid, 205 Psychomotor, 815
Mecamylamine, 415, 693 Noncompetitive NMDA antagonists, 561 Psychostimulant, 901
Medial preoptic area (MPOA), 681 Noradrenalin, 917 Pyruvate dehydrogenase complex, 917
Medial prefrontal cortex, 515 Norepinephrine, 69, 217, 263, 553, 687
Memory, 509, 739 N-Propyl-apomorphine, 175 Quercetin, 231
Meperidine, 535 NS-3 (CG3703), 929 Quinelorane, 681
MEPQ, 647 Nuclear proteins, 231 Quinine, 505
Mesocorticolimbic dopamine system, 491 Nucleus accumbens, 397, 681, 835 Quinolinic acid, 309, 739
Metabolic mapping, 37 Nucleus basalis magnocellularis, 739 Quinoxalines, 153
Metergoline, 69 Quinpirole, 77, 843
Methadone, 535 Odor conditioning, 463 Quipazine, 21
Methamphetamine, 97 1-(m-chlorophenyl)-biguanide, 835
Methylazoxymethanol, 869 Open field, 429 Rabbit, 577, 877
Methylene blue, 133 Open field behavior, 747, 795 Raclopride, 681
Methyl naltrexone, 491 Operant behavior, 301, 647 Radial-arm maze, 119, 345, 369, 415, 667,
Mice, 49, 313, 457, 525, 601, 747, 753, 947 Operant conditioning, 111 739
Microdialysis, 97, 835 Opiate, 387 Radial arm maze task, 929
Microencephaly, 869 Opioid peptides, 705 Random-ratio schedules, 941
Microinjection, 759 Opioid receptor, 535 Rat(s), 29, 69, 83, 111, 133, 153, 165, 199,
Midazolam, 481, 571 Opioid tolerance, 57 205, 263, 271, 285, 331, 359, 379, 429,
MK-801, 13, 133, 291, 345, 429, 635, 781, Opioids, 379, 491, 699 435, 463, 549, 571, 581, 611, 667, 681,
901, 909 Organophosphates, 443 705, 759, 789, 917, 923, 929
Moclobemide, 245 Organophosphorus, 647 Rat brain, 65, 339
Monkey, 301 Ovariectomy, 279 Rat brain areas, 183
Monoamine metabolites, 421 Oxide, 133 Rat strains, 699
Monoamine oxidase A, 421 Oxotremorine, 279 Reactivity, 767
Monoamine oxidase B, 421 Oxycodone, 535 Rearing, 149, 359
Monoamine reuptake inhibition, 687 Rearing conditions, 767
Monoamines, 421 PA, 935 Rebound changes in discriminative states,
Morphine, 49, 57, 103, 469, 491, 505, 699, Pain, 323, 469, 577 77
715 Palatability, 505 Rebound effects, 571
Morris water escape task, 111 Pancreas, 139 Receptor binding, 435
Morris water maze, 429, 667, 747 Panic, 235 Receptor supersensitivity, 175
Motivation, 301 Paralysis, 387 Red nucleus lesions, 29
Motor activity, 97, 647 Paraventricular nucleus, 641 Reference memory, 345, 415, 667, 739
Motor behavior, 429, 617 Parkinson’s disease, 617 Reinforcement, 827
Mouse, 3, 111, 249, 291, 297 Passive avoidance, 297, 647, 667 Repeated acquisition, 509
Mouse brain, 529 Passive avoidance response, 623 Resistance, 947
Mouse’s ambulation, 799 p-Chlorophenylalanine, 9 Response timing, 165
MPTP, 581 pCl-DPDPE, 359 Restraint stress, 699
p-Opioid peptide agonists, 149 Penile erection, 709 Reward, 457, 505
Muscarinic receptor agonists, 119 Pentobarbital, 391, 525 Rhesus monkey, 953
Pentylenetetrazol, 153, 363 Risk assessment, 235
N°-Phenylisopropyladenosine (L-PIA), 133 Performance, 443 RO 15-3505, 557
Naloxone, 675, 715 Perifornical hypothalamus, 641 RU 35 926 (CI-979), 119
Naltrexone, 535 Phagocytosis, 821 Running wheels, 725
Natural killer cell activity, 821 Phencyclidine, 291, 435
Neonatal 6-hydroxydopamine, 861 Phentolamine, 255 S 14506, 211
Neonatal, 159 Phenylethylamine, 421 S 14671, 211
Neuroactive steroids, 463 Phosphorylation, 231 Salbutamol, 69
Neuroleptic drugs, 565 Physostigmine, 415, 739, 929 SAM, 623
Neuropeptide Y, 641 Pigeons, 271 Sardinian alcohol-preferring rats, 21
Neuropeptides, 705 Pigeon conflict, 211 SART stress, 849
Neurosteroid, 463 Pirenperone, 235 Sarthran, 593
Neurotensin, 891 Place conditioning, 457 SCH 23390, 521, 681, 759, 781, 799
Neurotoxicity, 387 Place preference, 827 SCH 39166, 69
Neurotransmitters, 917 Platelet density distribution, 217 Schedule-controlled behavior, 481
Nexus, 473 Platelet function, 217 Schizophrenia, 561
N°-monomethyl-L-arginine, 309, 457 Postnatal handling, 199 Scopolamine, 271, 345, 415, 739, 929
Nicotine, 509 Posttreatment, 799 SDZ 208-911, 661
Nicotinic, 369 Potassium channels, 843 SDZ 208-912, 661
Nicotinic acetylcholine receptor, 693 Prazosin, 69, 255, 263 Secretin, 469
NIK247, 623, 923 Pregnancy, 753 Seizures, 133, 153, 313, 781
Nisoxetine, 69 Prenatal, 721 Selenium deficiency, 747
Nitric oxide, 309 Pretreatment, 443 Self-administration, 687, 941, 953
VI SUBJECT INDEX
Seminal emission, 709 Striatum, 3, 97, 397, 581, 767 Time, 271
Senktide, 21 Subjective, 323, 815 Time-course, 285, 635
Sensitization, 781, 901 Sulpiride, 781 Time discrimination, 165
Sensory-motor function, 103 Supersensitivity, 535 Time perception, 301
Serotonergic system, 183 Swiss-Webster mouse, 235 TimeWand, 509
Serotonin, 69, 183, 235, 687, 313, 301, 515, Switch-off behavior, 317 Tolerance, 363, 469, 481
641, 807, 835, 917 Symbol digit substitution, 189 Toluene, 97
Serotonin precursor and metabolite, 183 Synaptosomes, 57 Tonic immobility, 795
Sertindole, 353 Toxicity, 781
7-Nitroindazole, 133 T-maze, 345 Transient amnesia, 119
7-OH-DPAT, 545 T;, 885 TRH, 929
Sex differences, 635 T,, 885 Turning, 3
Sexual behavior, 439, 529, 545, 681, 709 Tacrine, 935 Tyrosine hydroxylase, 775
Short-term memory, 301 Tail flick, 469, 855
Short-sleep, 525 Tail skin temperature, 83 U50,488H, 57
Simultaneous administration, 799 Taste, 505 Ultrasonic vocalizations, 463
6-Hydroxydopamine, 159 Taste reactivity, 505 Upregulation, 535
6-OHDA lesions, 3 TCP, 429
Sleep, 877 Teleosts, 885 Ventral tegmental area, 491
Sleep apneas, 133 Temperature, 693 Virus, 947
Sleep-wake states, 353, 571 Temperature regulation, 255, 263 Vitamin B-6, 753
Sodium nitroprusside, 309 Temporal memory, 271 Volunteer, 323, 815
Spatial learning, 103 Terguride, 661
Spatial memory, 429 TH,, 947 WAG /Rij strain, 571
Spike-wave discharges, 353, 571 TH), 947 Water maze, 103
Spinal cord, 57, 387 THA, 119 Wet dog shakes, 21
Spinal rat, 855 Thermal balance, 255 Withdrawal, 103, 407, 941
Spinal transection, 709 Thiorphan, 675 Working memory, 119, 271, 345, 415, 557,
Spiperone, 77, 175 Third ventricle, 593 667, 739
Spontaneously hypertensive rats, 869 Thirst, 593
Squirrel monkeys, 661, 843 3a-Hydroxy-5a-pregnan-20-one, 463 YM-09151-2, 799
SR 141716A, 3 3-Bromopyruvate, 917 YM796, 623
Stereotypy, 149, 359 3,4-Diaminopyridine, 739 Yohimbine, 69, 255, 263
Stimulus properties of drugs, 285 3,4-Methylenedioxyphenyl-2-butanamine, Yoked control, 827
Stress, 65, 297, 331, 491, 821, 849 477
Stress-induced analgesia, 675 Thyroid, 885 Zolpidem, 571
Striatal and cortical catecholamines, 861 Thyroid hormones, 885 Zucker rat, 255
PHARMACOLOGY BIOCHEMISTRY
& BEHAVIOR
VOLUME 51 1995
AUTHOR INDEX
Abood, L., 369 Cain, D. P., 13 Drucker, P. C., 463 Hafif, N., 667
Abraham, S., 667 Caldarone, B. J., 407 Dubuc, P. U., 255 Haller, J., 789
Abrahamsen, G. C., 407 Callahan, P. M., 759 Durden, D. A., 421 Harding, S., 593
Advokat, C., 855 Campbell, A. D., 891 Dussaubat, N., 279 Hargreaves, E. L., 13
Ahlenius, S., 545 Campi, C. C., 611 Duttaroy, A., 535 Hasegawa, T., 309
Airaksinen, M. M., 529 Carey, R. J., 901 Dworkin, S. I., 379 Hata, T., 849
Al-Khatib, I., 245 Carley, D., 125 Dwoskin, L. P., 397 Hatsukami, D., 387
Allen, R. R., 310 Carli, G., 577 Head, E., 421
Aloisi, A. M., 577 Carlisle, H. J., 255, 263 Heal, D. J., 565
Alonso-Bedate, M., 885 Caul, W. F., 77 Egawa, M., 935 Hennig, J., 217
Alonso-Gomez, A. L., 885 Cazala, P., 49 Eguchi, J., 935 Henry, C., 103
Erscheid, P. M., 397
Amann, K., 103 Cebeira, M., 731 Hermans, I., 165
Anderson, W. R., 387 Chan, K., 535 Erwin, V. G., 891 Hill, T. J., 391
Apfelbaum, J. L., 323, 815 Cheetham, S. C., 565 Escorihuela, R. M., 199 Hisanaga, N., 97
Appel, J. B., 65 Chen, S.-W., 499 Esposito, G., 581 Hoffman, B. B., 439
Arenas, M. C., 601 Chew, B. H., 37 Holtzman, S. G., 699
Aslan, N., 715 Ciccocioppo, R., 21 Hooke, L. P., 387
Fernandez-Rial, J. C., 821
Ates, N., 353 Clark, C. R., 375, 473, 477 Hoyer, S., 917
Fernandez-Ruiz, J. J., 731
Clark, J. T., 439 Huang, J., 97
Fernéz-Teruel, A., 199
Clarke, G. D., 611 Huffman, E. M., 77
Babarczy, E., 469 Ferraz, M., 709
Clarke, S. N. D. A., 505 Hull, E. M., 681
Balboa, J. L., 821 Ferré, P., 199
Clement, C., 217 Huston, J. P., 901
Ferré, S., 205
Banks, W. A., 139 Coalson, D., 815
Bannon, A. W., 693 Ferretti, C., 69
Coenen, A. M. L., 353, 571 Ichihara, G., 97
Bardo, M. T., 397 Commissaris, R. L., 391, 635 Fibiger, H. C., 331 Irifune, M., 291
Barrett, J. E., 843 Consolo, S., 29 File, S. E., 1 Ishii, R., 923
Filliat, P., 429
Barrett, R. J., 77 Coppens, H. J., 175 Itoh, E., 849
Barzaghi, F., 119 Corbett, R., 561 Fisher, A., 667 Ivy, G. O., 421
Flagmeyer, I., 11
Bass, P. P., 57 Coscina, D. V., 641 Iwai, A., 623
Bauer, T., 509 Costi, P., 29 Forster, M. J., 557 Iwai, K., 935
Beck, C. H. M., 331 Francon, D., 571
Coutts, R. T., 89
Bednar, I., 9 Cunningham, C. L., 827 Frank, S., 627 Jackson-Smith, P., 103
Beninger, R. J., 739 Frederick, D. L., 310
Cunningham, K. A., 759
Fregly, M. J., 83 Jalava, K.-M., 189
Beresford, R. A., 375
Berkman, K., 715 Freire-Garabal, M., 821 Jaspan, J. B., 139
Blanchard, D. C., 235 D’Anci, K., 725 Fresu, L. G., 581 Jhamandas, K., 739
Blanchard, R. J., 235 Diaz-Véliz, G., 279 Froelich, L., 917 Jiang, W., 473, 477
Dai, H., 901 Fujimoto, J. M., 655 Johnson, B. J., 617
Blanchet, G., 429
Blank, K. J., 947 Dall’Olio, R., 183 Fukuda, T., 291 Jones, C. R. N., 387
David, V., 49 Jones, D. J., 553
Blengio, M., 69
Boast, C. A., 345 Davidson, J. M., 439 Jones, J. R., 77
Davies, M. F., 499 Gaggi, R., 183 Jung, A., 235
Boegman, R. J., 739
Davis, B. A., 421 Gancedo, B., 885
Boulton, A. B., 421
Davis, T., 535 Garcia, E., 199 Kameyama, T., 705
Bowling, S. L., 397
Brao, M. L., 317 Decker, M. W., 693 Garcia, L., 731 Kamijima, M., 97
Brandeis, R., 667 Delgado, A. J., 885 Gariépy, J.-L., 767 Kanarek, R. B., 725
De Pedro, N., 885 Gaspard, T. M., 379 Karadag, H. C., 245
Brannan, S. K., 553
DePoortere, H., 571 Gendreau, P. L., 767 Kastin, A. J., 139
Broadbent, J., 379
DeRuiter, J., 473, 477 Gessa, G. L., 21 Kebabian, J., 953
Brocco, M., 211
DeSole, M. S., 581 Ghi, P., 65 Kesner, R. P., 103
Bronson, M. E., 473, 477, 481
Deutsch, S. I., 133, 909 Gianni, A. M., 183 Kimura, K., 929
Brown, C. M., 641
De Wit, H., 941 Gillam, M. P., 310 Klafta, J., 815
Bryan, S. K., 759
Dey, D., 217 Giménez-Llort, L., 205 Kleinrok, Z., 29
Buckner, E., 635
Dieckwisch, J., 217 Grahame, M. J., 827 Kleinsorge, R. J., 391
Burke, T. F., 435
Burkhart-Kasch, B., 827 Ding, A., 917 Grella, G., 581 Koetzner, L., 133, 909
Doctor, B. P., 647 Griebel, G., 235 Koff, J. M., 721
Busker, R. W., 443
Dokmeci, D., 245 Groen, B., 443 Kolasa, K., 29
Buxton, S. T., 397
Dokmeci, I., 245 Gross, P. M., 37 Kolta, M. G., 525
Buzzard, S., 435
Drinkenburg, W. H. I. M., Grupp, L. A., 593 Komatsu, T., 935
Byrne, A., 89
571 Gunther, K. L., 693 Kondo, H., 97
Vill AUTHOR INDEX
Koob, G. F., 1 Monti, D., 125 Romero, J., 731 Takeuchi, Y., 97
Korf, J., 175 Mora, S., 279 Roncada, P., 183 Tamura, M., 929
Kovera, C., 509 Mori, E., 705 Rose, J. E., 369 Tang, X. C., 415
Kramer, G. L., 553 Moriarty, D. D., 795 Rosellini, R. A., 407 Tarssanen, M., 189
Krost, M., 901 Morn, C., 133, 909 Rosenberg, H. C., 363 Telegdy, G., 469
Kubova, H., 153 Moses, J., 681 Rosenzweig-Lipson, S., Tella, S. R., 687
Kueny, T., 439 Murphy, M. P., 421 843 Tessel, R. E., 861, 869
Kuribara, H., 799 Myers, R., 891 Rosse, R. B., 133 Thapar, P., 323
Rotunda, R., 509 Tobefia, A., 199
LaForge, R. R., 345 Nabeshima, T., 309 Rowl, N. E., 83 Togashi, H., 515
Lal, H., 557 Najimi, M., 297 Rowlett, J. K., 397 Toker, F., 715
Langley, L. K., 509 Nakagawa, Y., 929 Ruehl, W. W., 421 Toth, L. A., 877
Larochelle, J. S., 775 Nakahara, D., 97 Rupani, G., 815 Tumas, K. M., 947
Larsson, K., 545 Nakamura, T.-A., 309 Russell, B. R., 375 Tuimer, N., 775
Laschefski, U., 217 Naruse, T., 923 Rutherford, D., 855 Tupala, E., 529
Lee, N. M., 387 Netter, P., 217 Rybak, L. P., 627
Lefebvre De Ladonchamps, Nishikawa, H., 849
Ukai, M., 705
B., 211 Nomoto, M., 291 Saano, V., 529 Ukai, Y., 929
Le Fur, G., 3 Nufiez, J. F., 199 Sagen, J., 339
Ulugol, A., 245
Lejeune, H., 165 Nufiez-Iglesias, M. J., 821 Saito, H., 515
Uphouse, L., 807
Levin, E. D., 369 Saito, I., 97 Urichuk, L. J., 89
Lewis, M. H., 767 Oakes, R. A., 457 Saito, K.-I., 935
Lichtor, J. L., 815 Oberler, C., 119 Saito, T., 781
Vachova, D., 153
Lindqvist, E., 159 Ogasawara, T., 929 Samaan, S. S., 525
Van De Kamp, J. L., 753
Loew, G. H., 499 Ogg, B. G., 675 Sangha, S., 675
Loucks, J. A., 681 Ogren, S. O., 159 Santi, A., 271 van der Staay, F. J., 111
Loupe, P. S., 861, 869 Oktay, $., 715 Santos, R., 709 Van Groll, B. J., 57
Van Helden, H. P. M., 443
Lukacs, L. G., 909 Onat, F., 715 Sapir, M., 667
Van Luijtelaar, E. L. J. M.,
Luthman, J., 159 Ono, M., 541 Saraco, M. G., 223
353, 571
Ono, Y., 97 Satoh, H., 747
Vanakoski, J., 189
Mackevicius, A. S., 953 Opper, C., 217 Schechter, M. D., 285, 313,
Velichkova, A. A., 231
Mailman, R. B., 767 Oz, N., 667 521, 549
VeliSek, L., 153
Maldonado, H., 223 Ozawa, Y., 623 Schmierer, D. M., 375
Mallet, P. E., 739 Schneider, J. S., 617
Mare$, P., 153 Palou, A.-M., 119 Schreiber, R., 211 Wananukul, W., 387
Marks-Kaufman, R., 725 Panerai, A. E., 577 Schroeder, S. R., 861, Watanabe, C., 747
Marley, R. J., 781 Panocka, I., 21 869 Watanabe, S., 541
Martin, K. F., 565 Park, C. H., 909 Schutz, A. D., 407 Watson, H. L., 681
Martinez, E., 205 Parker, L. A., 505 Sebens, J. B., 175 Weaver, D. F., 37
Martin-Iverson, M. T., 89 Parra, A., 601 Shah, S., 535 Weed, M. R., 953
Massi, M., 21 Patel, H. R., 557 Shaham, Y., 491 Weider, J. M., 463
Mastropaolo, J., 133, 909 Patterson, T. H., 323 Shibata, E., 97 Weise, L., 271
Masuda, C. K., 235 Paule, M. G., 301 Shibata, S., 541 Welch, S. P., 49
Maswood, S., 807 Peacock, V., 617 Shih, T.-M., 249 Wesemann, S., 217
Matsumoto, M., 515 Pentel, P. R., 387 Shimizu, T., 291 Wessinger, W. D., 435
Mattila, M. J., 189 Petty, F., 553 Shimosato, K., 781 West, W. B., 57
Matuszewich, L., 681 Pey, G. N., 339 Simon, V. M., 601 Wilson, A. L., 509
Maurer, S. A., 345 Pey, S. C., 339 Sircana, S., 581 Wirsching, B. A., 739
McBride, C., 835 Phillips, I., 565 Skarsfeldt, T., 353 Wolthuis, O. L., 443
McCarten, J. R., 509 Phillips, T. J., 827 Smith, E. R., 439 Womer, D. E., 891
McDonough, J. H., JR., 249 Pirec, V., 323 Smolen, A., 753 Woolfolk, D. R., 699
McEachron, D. L., 947 Poignant, J. C., 165 Sdédersten, P., 9 Woolverton, W. L., 953
McFalls, E., 509 Poncelet, M., 3 Soliman, K. F. A., 525 Wu, P. H., 421
McLaurin, B. I., 149, 359 Portaleone, P., 69 Somani, S. M., 627
McMiller, L. V., Jr., 391 Prather, P. L., 557 Soubrié, P., 3 Xie, Z., 635
McNaughton, N., 375 Prystowsky, M. B., 947 Souilhac, J., 3
Xiong, Z. Q., 415
Meehan, S. M., 313, 521 Przypek, J., 725 Spealman, R., 661
Melo, L. L., 317 Stefanini, E., 21
Meyer, M. E., 149, 359 Quartermain, D., 297 Stein, E., 667 Yajnik, S., 815
Yamada, K., 309
M’Harzi, M., 111 Qureshi, G. A., 9 Stevens, C. W., 675
Yamaguchi, T., 623
Miele, E., 581 Stewart, G., 807
Yamamoto, M., 623
Miele, M., 581 Radulovacki, M., 125 Stewart, J., 491
Yoburn, B. C., 535
Migheli, R., 581 Rady, J. J., 655 Stino, F. K. R., 525
Milgram, N. W., 421 Rago, L., 529 Stock, H. S., 407 Yoshioja, M., 515
Young, C., 815
Millan, M. J., 211 Ramos, J. A., 731 Stock, M. J., 255, 263
Yu, P. H., 421
Miller, A., 553 Reimer, A. R., 89 Stodgell, C. J., 861
Miller, L. G., 721 Ren, X., 339 Stoker, D., 439 Yuasa, T., 935
Minamoto, Y., 541 Rettori, M.-C., 165 Stone, E. A., 297
Mitchell, S. H., 941 Rey-Méndez, M., 821 Storch, F. E., 345 Zacny, J. P., 323, 815, 941
Mizinga, K. M., 525 Richelle, M., 165 Strand, E. J., 77 Zangani, D., 581
Mocaér, E., 165 Rinaldi-Carmona, M., 3 Suzuki, M., 623 Zecca, L., 29
Monley, J., 509 Risinger, F. O., 457 Szabo, G., 469 Zimmerberg, B., 463